{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CRISPR Therapeutics AG
CRISPR Therapeutics Hits Day High with 8.24% Surge in Stock Price
CRISPR Therapeutics AG's stock surged today, contrasting with a slight decline in the S&P 500. While the company has seen modest weekly gains, its monthly performance has dipped. Despite challenges like low return on equity and recent financial losses, it has outperformed the S&P 500 over the past year.
CRISPR Therapeutics Hits Day Low of $54.91 Amid Price Pressure
CRISPR Therapeutics AG's stock fell significantly today, reflecting ongoing challenges for the company. Despite a positive annual return, its long-term performance shows a notable decline. Financial metrics indicate low profitability, with consecutive quarterly losses and a substantial drop in net sales, while the company faces a challenging financial landscape.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of October 31, 2025, CRISPR Therapeutics AG shows a bullish technical trend, supported by positive MACD indicators and a strong year-to-date return of 43.32%, despite recent underperformance compared to the S&P 500 and mixed signals from other indicators.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of October 31, 2025, CRISPR Therapeutics AG shows a bullish technical trend, supported by positive daily moving averages and a strong year-to-date return of 57.44%, despite recent underperformance against the S&P 500.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of October 31, 2025, CRISPR Therapeutics AG shows a bullish technical trend, with strong performance indicators despite some mixed signals, having returned 62.58% year-to-date and 37.94% over the past year, significantly outperforming the S&P 500.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of October 31, 2025, CRISPR Therapeutics AG shows a bullish trend driven by strong daily moving averages and a bullish weekly MACD, despite recent underperformance compared to the S&P 500 and some caution from weekly KST and Dow Theory signals.
CRISPR Therapeutics Hits Day Low of $64.80 Amid Price Pressure
CRISPR Therapeutics AG's stock fell significantly today, contrasting with the S&P 500's stability. Despite a strong yearly performance, the company has faced challenges, including negative results over the past four quarters, a substantial decline in net sales, and low profitability indicators.
CRISPR Therapeutics Hits Day High with 8.72% Surge in Stock Price
CRISPR Therapeutics AG's stock surged on October 8, 2025, achieving an intraday high and outperforming the S&P 500. Despite impressive short-term gains and significant year-to-date growth, the company faces challenges, including low return on equity and declining net sales and profits over the past year.
CRISPR Therapeutics AG Hits New 52-Week High of $78.47
CRISPR Therapeutics AG has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of approximately USD 4.93 billion, remains notable in the Pharmaceuticals & Biotechnology sector despite ongoing losses and a lack of dividends.
CRISPR Therapeutics AG Hits New 52-Week High of $73.95
CRISPR Therapeutics AG has achieved a new 52-week high, reflecting a significant increase from its previous low. Operating in the Pharmaceuticals & Biotechnology sector, the company has a market capitalization of approximately USD 4.93 billion and has shown a positive one-year performance, despite being loss-making.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of August 13, 2025, CRISPR Therapeutics AG's technical trend is mildly bullish, supported by positive indicators like a bullish MACD, Bollinger Bands, and strong year-to-date performance of 59.91% compared to the S&P 500's 12.22%.
Is CRISPR Therapeutics AG overvalued or undervalued?
As of August 8, 2022, CRISPR Therapeutics AG is considered overvalued with a risky valuation grade, highlighted by a negative P/E ratio of -13.27 and a negative ROE of -21.08%, despite a strong year-to-date stock return of 59.91%.
Is CRISPR Therapeutics AG overvalued or undervalued?
As of August 8, 2022, CRISPR Therapeutics AG is considered overvalued and risky due to its negative P/E ratio and poor financial metrics, despite a year-to-date stock return of 15.73% that outperforms the S&P 500's 2.44%.
Is CRISPR Therapeutics AG technically bullish or bearish?
As of June 3, 2025, the technical trend is mildly bearish, with daily moving averages and monthly indicators signaling bearish sentiment, despite some short-term strength indicated by weekly MACD and Bollinger Bands.
Who are in the management team of CRISPR Therapeutics AG?
As of March 2022, the management team of CRISPR Therapeutics AG includes Dr. Rodger Novak (Chairman, President, Co-Founder) and Dr. Samarth Kulkarni (CEO, Director), along with independent directors Dr. Ali Behbahani, Dr. Bradley Bolzon, Dr. Simeon George, Mr. John Greene, and Dr. Katherine High.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is a Switzerland-based gene-editing company focused on developing gene-based medicines for serious diseases. As of March 2025, it reported net sales of $1 million and a net loss of $136 million, with a market cap of approximately $3.74 billion.
How big is CRISPR Therapeutics AG?
As of Jun 18, CRISPR Therapeutics AG has a market capitalization of 3,737.84 million, with net sales of 37.67 million and a net profit of -385.66 million over the latest four quarters. The company reported shareholder's funds of 1,932.08 million and total assets of 2,242.03 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
